Predicted protein targets (top 4)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | QPCT | Q16769 | 15/20 | 0.68 |
| ▸ | QPCTL | Q9NXS2 | 4/20 | 0.47 |
| ▸ | MAOB | P27338 | 1/20 | 0.46 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.45 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL3641720 | 1.00 | QPCT (0.68) | QPCTQPCTLMAOBALDH1A1 | |
| SCHEMBL3635255 | 0.91 | QPCT (0.68) | QPCTQPCTL | |
| SCHEMBL11892032 | 0.91 | QPCT (0.68) | QPCTQPCTL | |
| SCHEMBL11892035 | 0.90 | QPCT (0.68) | QPCTQPCTL | |
| SCHEMBL3637926 | 0.90 | QPCT (0.68) | QPCTQPCTL | |
| SCHEMBL11892043 | 0.88 | QPCT (0.53) | QPCTQPCTL | |
| SCHEMBL3636935 | 0.88 | QPCT (0.53) | QPCTQPCTL | |
| SCHEMBL11892039 | 0.87 | QPCT (0.52) | QPCTQPCTL | |
| SCHEMBL3636915 | 0.87 | QPCT (0.52) | QPCTQPCTL | |
| SCHEMBL11892046 | 0.87 | QPCT (0.52) | QPCTQPCTL |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 4 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-8227498-B2 | imidazole derivatives; Alzheimer's Disease, Down syndrome and Huntington's Disease; hypotensive agents; sleeping and eating disorders, anxiolytic agents, antidepressants, antiepileptic agents; drug abuse/withdrawl; 2-cyano(4-ethylphenyl)-3-(3-(5-methyl-1H-imidazol-1-yl)propyl)guanidine | PROBIODRUG AG (DE) | 2012-07-24 | — | — | US | disclosed |
| US-8227498-B2 | imidazole derivatives; Alzheimer's Disease, Down syndrome and Huntington's Disease; hypotensive agents; sleeping and eating disorders, anxiolytic agents, antidepressants, antiepileptic agents; drug abuse/withdrawl; 2-cyano(4-ethylphenyl)-3-(3-(5-methyl-1H-imidazol-1-yl)propyl)guanidine | PROBIODRUG AG (DE) | 2012-07-24 | — | — | US | disclosed |
| US-20080267912-A1 | NOVEL INHIBITORS OF GLUTAMINYL CYCLASE | PROBIODRUG AG (DE) | 2008-10-30 | — | — | US | disclosed |
| US-20080267912-A1 | NOVEL INHIBITORS OF GLUTAMINYL CYCLASE | PROBIODRUG AG (DE) | 2008-10-30 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20080267912-A1 | NOVEL INHIBITORS OF GLUTAMINYL CYCLASE | GLS, GLS2, QPCT | QPCT 3/4885QPCTL 14/4885MAOB 1307/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.